Tuesday June 26, 8:02 pm Eastern Time
Press Release
SOURCE: Aviron
FDA Advisory Committee Scheduled to Review FluMist(TM) July 26-27
MOUNTAIN VIEW, Calif., June 26 /PRNewswire/ -- The Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to evaluate FluMist(TM), Aviron's investigational intranasal influenza vaccine, at their July 26-27 meeting, according to today's Federal Register.
On October 31, 2000, Aviron submitted a Biologics License Application to the FDA seeking licensure of FluMist(TM) to prevent influenza in healthy children and healthy adults.
Aviron is a biopharmaceutical company based in Mountain View, California, focused on the prevention of disease through innovative vaccine technology.
To receive an index and copies of recent press releases, call Aviron's News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional information about the company can be located at aviron.com .
SOURCE: Aviron |
